See the Complete Picture.
Published loading...Updated

Oral Norovirus Vaccine Candidate Successfully Tested in Human Challenge Trial

Summary by Medical Xpress
Vaxart Inc., in collaboration with researchers from multiple academic institutions, evaluated the VXA-G1.1-NN vaccine against norovirus infection. Findings show a 30% reduction in infection rates among vaccinated participants compared to those receiving a placebo, along with reduced viral shedding and increased levels of protective antibodies in blood and mucosal tissues.

8 Articles

All
Left
1
Center
2
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources are Center
67% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

NewScientist broke the news in Baltimore, United States on Wednesday, May 14, 2025.
Sources are mostly out of (0)